CTOs on the Move

Octapharma USA

www.octapharma.com

 
Octapharma is committed to promoting excellence in patient care and providing valuable information to the medical and patient community. This will help to better manage the treatment of disease and to improve patient safety and population health
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

GLSA | Global Life Sciences Alliance

Global Life Sciences Alliance (GLSA) is a dynamic and collaborative network of global CROs and clinical research vendors specializing in innovative solutions for Sponsors and CROs.The GLSA Team and Network accelerates clinical research timelines through innovation, leveraging extensive experience to foster collaboration and deliver superior outcomes. By mitigating the risks of vendor selection, GLSA ensures exceptional results for clinical trials.

Hatec Inc

Hatec Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Business Resources

Medical Business Resources, Inc., established in 1994 as a medical billing service, offers a cost effective solution to the complexities of medical practice administration. Our services allow providers to focus upon delivering health care with the confidence that administrative support services are in place.

xbiotech usa inc

xbiotech usa inc is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elicio

Elicio is committed to transforming the lives of patients and their families by re-engineering the body`s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body`s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio`s lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio`s Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.